Description: Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. It also focuses on generic oncology injectable products. The company offers generic oncology products, such as temozolomide, capecitabine, and erlotinib. It also provides injectable generic chemotherapy drugs, such as pemetrexed for the treatment of non-small cell lung cancer and other indications; and bortezomib to treat multiple myeloma and other indications. In addition, the company develops PARP-1 inhibitors for cancer treatment. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Home Page: www.waverleypharma.com
4-1250 Waverley Street
Winnipeg,
MB
R3T 6C6
Canada
Phone:
204 928 7907
Officers
| Name | Title |
|---|---|
| Mr. Larry Thiessen M.B.A. | President, CEO & Director |
| Mr. Haaris Uddin B.Com., CPA | Chief Financial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1099 |
| Price-to-Sales TTM: | 5.041 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |